Prostate Cancer

Maha H. Hussain, MBChB, from the University of Michigan Comprehensive Cancer Center, explains that care should be multi- and interdisciplinary, in order to provide the best possible outcomes.

Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.

The FDA has expanded the approval for enzalutamide to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.

Terence Friedlander, MD, specializes in understanding the basic biology of genitourinary cancer, in particular cancer of the bladder and prostate, in developing new treatments and studying new ways to overcome treatment resistance.

The year was 1989, and I was one year away from finishing six years of residency in general surgery and urology.

ASCO and CCO have released an updated guideline focused on the treatment of men with mCRPC that incorporates information about 6 recently approved drugs that have significantly changed the therapeutic landscape.

Although hormone-targeting strategies have been a mainstay of prostate and breast cancer therapies for decades, an improved understanding of the mechanisms underlying these malignancies has led researchers to focus fresh attention on the complex activity of the androgen receptor (AR) as a point of attack.

Practice-changing trends in the combined use of androgen deprivation therapy (ADT) and radiation therapy (RT) for the treatment of prostate cancer were highlighted recently in a review paper by Mack Roach III, MD, a professor of Radiation Oncology and Urology and chair of the Department of Radiation Oncology at the University of California, San Francisco.

Cabozantinib (Cometriq) failed to significantly extend overall survival compared with prednisone as a treatment for men with metastatic castration-resistant prostate cancer.

Sipuleucel-T (Provenge), an immunotherapy tailor-made for men with metastatic castration-resistant prostate cancer (mCRPC) using their own white blood cells, is just as potent if it is manufactured while a patient is taking enzalutamide (Xtandi), and the two drugs seem to boost immunity more effectively when administered together.

Robert Petit, PhD, the chief scientific officer at Advaxis, provides insight into the ADXS-PSA immunotherapy and the rationale behind the combination study with pembrolizumab.

Sipuleucel-T (Provenge) is effective when given either before or after androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer (BRPC) who face a high risk of developing metastases, a study has found.

Advaxis and Merck have entered into a clinical trial collaboration agreement to evaluate the combination of two novel immunotherapies for the treatment of patients with metastatic castration-resistant prostate cancer.

A physician's perspective, and the therapies he most often prescribes, can have a big influence on whether his patients with low-risk prostate cancer are treated or put on active surveillance, a study has found.

Prostate cancer that emerges when a man is 55 years of age or younger is a distinct phenotype of the disease, and should be treated and researched accordingly,

In recent studies, robotic-assisted surgery was explored as a treatment for both prostate and kidney cancers.

Men diagnosed with prostate cancer after being diagnosed with depression were less likely to undergo definitive treatment for their cancer and had worse overall survival.

As fellows in oncology, we are constantly required to assimilate data, interpret diagnostic tests, decide on appropriate treatment regimens, and employ compassionate care in an increasingly truncated allotment of time.

Research from Chile suggests that low levels of free testosterone indicate that an apparently low-risk case of prostate cancer will require treatment.

Stephen J. Freedland, MD, associate professor, Duke University, discusses an analysis presented at the 2014 AUA Annual Meeting that looked at carbohydrate intake, glycemic index, and prostate cancer risk.

The American Urological Association (AUA) has added recommendations for the use of radium-223 to its treatment guidelines for castration-resistant prostate cancer

Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetics, discusses a study that looked at predicting radical prostatectomy outcomes.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses the results of a phase II trial that examined prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC) patients.

The 2nd Annual Giants of Cancer Careâ„¢ Awards were presented at a ceremony held on May 30 in Chicago. The event recognized 16 oncology heroes whose groundbreaking contributions to the field have improved the lives of patients with cancer.

When a patient develops advanced prostate cancer, that doesn't mean his urologist needs to bid him farewell.